Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

Peter H O'DonnellVassily TrubetskoyAshley Nurhussein-PattersonJulianne P HallAritro NathDezheng HuoGini F FlemingJames N IngleVandana G AbramsonP K MorrowAnna Maria StornioloAndres ForeroCatherine Van PoznakMinetta C LiuJenny C ChangDouglas E MerkelJeffrey M PeppercornHope S RugoE Claire DeesOlwen M HahnPhilip C HoffmanGary L RosnerR Stephanie HuangMark J RatainNancy CoxOlufunmilayo I OlopadeAntonio C WolffM Eileen DolanRita Nandanull null

Published in: Breast cancer research and treatment (2020)

This is the first cancer pharmacogenomic study to use phone-in self-reporting, permitting augmented toxicity characterization. Three germline toxicity SNPs were replicated, and several novel SNPs/genes having strong functional relevance were discovered. If further validated, these markers could permit personalized capecitabine dosing.

Keyphrases

clinical evaluation
genome wide
oxidative stress
dna repair
phase ii study
metastatic breast cancer
clinical trial
phase iii
dna methylation
squamous cell carcinoma
metastatic colorectal cancer
childhood cancer
adverse drug
squamous cell
clinical decision support
transcription factor
electronic health record